Silexion Therapeutics (SLXN) Competitors

$0.51 +0.03 (+6.74%)

As of 02:56 PM Eastern

SLXN vs. BDRX, LNAI, PCSA, BMRA, and XBIO

Should you buy Silexion Therapeutics stock or one of its competitors? MarketBeat compares Silexion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silexion Therapeutics include Biodexa Pharmaceuticals (BDRX), Lunai Bioworks (LNAI), Heatwurx (PCSA), Biomerica (BMRA), and Xenetic Biosciences (XBIO). These companies are all part of the "pharmaceutical products" industry.

How does Silexion Therapeutics compare to Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Silexion Therapeutics	N/A	-516.86%	-176.68%

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biodexa Pharmaceuticals has higher revenue and earnings than Silexion Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	13.94	-$8.42M	N/A	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$8.05	N/A

In the previous week, Silexion Therapeutics had 4 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 4 mentions for Silexion Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Silexion Therapeutics' average media sentiment score of 0.83 beat Biodexa Pharmaceuticals' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Silexion Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market.

Summary

Biodexa Pharmaceuticals beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to Lunai Bioworks?

Silexion Therapeutics (NASDAQ:SLXN) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, Lunai Bioworks had 2 more articles in the media than Silexion Therapeutics. MarketBeat recorded 6 mentions for Lunai Bioworks and 4 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.83 beat Lunai Bioworks' score of -0.16 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lunai Bioworks is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$8.05	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.05	N/A

Silexion Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Silexion Therapeutics' return on equity of -516.86% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 5.0% of Silexion Therapeutics shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Silexion Therapeutics beats Lunai Bioworks on 8 of the 12 factors compared between the two stocks.

How does Silexion Therapeutics compare to Heatwurx?

Silexion Therapeutics (NASDAQ:SLXN) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 5.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 2.4% of Heatwurx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Heatwurx's return on equity of -281.31% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Heatwurx	N/A	-281.31%	-200.80%

In the previous week, Silexion Therapeutics and Silexion Therapeutics both had 4 articles in the media. Heatwurx's average media sentiment score of 1.00 beat Silexion Therapeutics' score of 0.83 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Silexion Therapeutics	Positive
Heatwurx	Positive

Silexion Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Heatwurx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Heatwurx has a consensus target price of $25.00, suggesting a potential upside of 839.85%. Given Heatwurx's higher possible upside, analysts plainly believe Heatwurx is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heatwurx is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$8.05	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Summary

Silexion Therapeutics and Heatwurx tied by winning 5 of the 10 factors compared between the two stocks.

How does Silexion Therapeutics compare to Biomerica?

Silexion Therapeutics (NASDAQ:SLXN) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Silexion Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Biomerica	-96.49%	-98.14%	-70.42%

Silexion Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

10.9% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 5.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biomerica has a consensus target price of $9.00, indicating a potential upside of 271.13%. Given Biomerica's higher probable upside, analysts clearly believe Biomerica is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biomerica has higher revenue and earnings than Silexion Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$8.05	N/A
Biomerica	$5.31M	1.41	-$4.97M	-$0.89	N/A

In the previous week, Silexion Therapeutics had 3 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for Silexion Therapeutics and 1 mentions for Biomerica. Silexion Therapeutics' average media sentiment score of 0.83 beat Biomerica's score of 0.67 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomerica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biomerica beats Silexion Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Silexion Therapeutics compare to Xenetic Biosciences?

Silexion Therapeutics (NASDAQ:SLXN) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

In the previous week, Silexion Therapeutics had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Silexion Therapeutics and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.05 beat Silexion Therapeutics' score of 0.83 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenetic Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Silexion Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 5.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has higher revenue and earnings than Silexion Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$8.05	N/A
Xenetic Biosciences	$2.98M	2.20	-$2.68M	-$1.20	N/A

Silexion Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market.

Summary

Xenetic Biosciences beats Silexion Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.68M	$3.38B	$6.39B	$12.33B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-0.06	19.03	21.06	25.70
Price / Sales	N/A	299.85	580.13	99.36
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	5.63	6.98	10.10	7.04
Net Income	-$11.91M	$24.45M	$3.55B	$335.04M
7 Day Performance	75.43%	3.76%	4.91%	2.69%
1 Month Performance	-48.00%	-0.17%	1.57%	1.49%
1 Year Performance	-96.57%	62.88%	36.63%	35.72%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	1.3546 of 5 stars	$0.51 +6.7%	N/A	-96.6%	$1.68M	N/A	N/A	N/A	Earnings Report Gap Down
BDRX Biodexa Pharmaceuticals	0.5601 of 5 stars	$3.70 -2.6%	N/A	-95.0%	$7.40M	$470K	N/A	20	Gap Down
LNAI Lunai Bioworks	0.3224 of 5 stars	$0.30 -3.5%	N/A	N/A	$7.35M	N/A	6.08	20	News Coverage Earnings Report Gap Down
PCSA Heatwurx	3.3385 of 5 stars	$2.61 +1.8%	$25.00 +859.7%	-57.4%	$7.18M	N/A	N/A	20	Gap Up
BMRA Biomerica	1.7341 of 5 stars	$2.32 +1.1%	$9.00 +288.8%	-30.5%	$7.15M	$5.31M	N/A	60	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. BDRX, LNAI, PCSA, BMRA, and XBIO

How does Silexion Therapeutics compare to Biodexa Pharmaceuticals?

Summary

How does Silexion Therapeutics compare to Lunai Bioworks?

Summary

How does Silexion Therapeutics compare to Heatwurx?

Summary

How does Silexion Therapeutics compare to Biomerica?

Summary

How does Silexion Therapeutics compare to Xenetic Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. BDRX, LNAI, PCSA, BMRA, and XBIO

How does Silexion Therapeutics compare to Biodexa Pharmaceuticals?

Is BDRX or SLXN more profitable?

Do insiders & institutionals have more ownership in BDRX or SLXN?

Which has preferable earnings and valuation, BDRX or SLXN?

Does the media refer more to BDRX or SLXN?

Do analysts rate BDRX or SLXN?

Which has more risk and volatility, BDRX or SLXN?

Summary

How does Silexion Therapeutics compare to Lunai Bioworks?

Does the media prefer SLXN or LNAI?

Which has higher valuation & earnings, SLXN or LNAI?

Which has more risk & volatility, SLXN or LNAI?

Do analysts rate SLXN or LNAI?

Is SLXN or LNAI more profitable?

Do institutionals and insiders hold more shares of SLXN or LNAI?

Summary

How does Silexion Therapeutics compare to Heatwurx?

Do institutionals and insiders hold more shares of SLXN or PCSA?

Is SLXN or PCSA more profitable?

Does the media refer more to SLXN or PCSA?

Which has more volatility & risk, SLXN or PCSA?

Do analysts prefer SLXN or PCSA?

Which has better earnings and valuation, SLXN or PCSA?

Summary

How does Silexion Therapeutics compare to Biomerica?

Is SLXN or BMRA more profitable?

Which has more risk and volatility, SLXN or BMRA?

Do institutionals and insiders believe in SLXN or BMRA?

Do analysts recommend SLXN or BMRA?

Which has preferable earnings & valuation, SLXN or BMRA?

Does the media refer more to SLXN or BMRA?

Summary

How does Silexion Therapeutics compare to Xenetic Biosciences?

Does the media refer more to SLXN or XBIO?

Is SLXN or XBIO more profitable?

Do insiders and institutionals believe in SLXN or XBIO?

Do analysts rate SLXN or XBIO?

Which has preferable valuation & earnings, SLXN or XBIO?

Which has more volatility & risk, SLXN or XBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools